Simultaneous integrated boost intensity-modulated radiotherapy for treatment of locally advanced non-small-cell lung cancer: a retrospective clinical study

被引:17
|
作者
Ji, K. [1 ,2 ]
Zhao, L. J. [2 ,3 ]
Liu, W. S. [2 ,3 ]
Liu, Z. Y. [2 ,3 ]
Yuan, Z. Y. [2 ,3 ]
Pang, Q. S. [2 ,3 ]
Wang, J. [2 ,3 ]
Wang, P. [2 ,3 ]
机构
[1] Tianjin Med Univ Canc Inst & Hosp, Dept Pain Relief, Natl Clin Res Ctr Canc, Tianjin, Peoples R China
[2] Tianjin Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China
[3] Tianjin Med Univ Canc Inst & Hosp, Dept Radiotherapy, Natl Clin Res Ctr Canc, Tianjin, Peoples R China
来源
BRITISH JOURNAL OF RADIOLOGY | 2014年 / 87卷 / 1035期
关键词
3-DIMENSIONAL CONFORMAL RADIATION; PHASE-III TRIAL; SEQUENTIAL CHEMORADIOTHERAPY; NODAL IRRADIATION; CONCURRENT; PNEUMONITIS; THERAPY; ESCALATION; CISPLATIN; SURVIVAL;
D O I
10.1259/bjr.20130562
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective: To evaluate the clinical efficacy and safety of simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) for patients with locally advanced non-small-cell lung cancer (LANSCLC). Methods: 48 patients with LANSCLC treated with SIB-IMRT from January 2010 to April 2012 were retrospectively analysed. A radiation dose of 45-63 Gy (median dose, 51.58 Gy) was delivered to the planning target volume (1.8-2.0 Gy daily fractions) simultaneously with 55.0-74.2 Gy (median dose, 63 Gy) to the planning gross tumour volume (2.00-2.25 Gy daily fractions). 45 patients received concurrent/sequential chemotherapy. The overall survival (OS), locoregional recurrence-free survival (LRFS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method. Treatment-related pneumonitis and oesophagitis were graded according to the Common Terminology Criteria for Adverse Events v. 4.0. Results: By 1 July 2013, 29 of the 48 patients were dead. The median follow-up time for the survivors was 28 months (19-44 months). The median OS and PFS were 21 and 14 months, respectively. The median LRFS time was not reached. The 2-year LRFS, OS and PFS were 62.5%, 45.1% and 28.0%, respectively. Two patients experienced Grade 3 treatment-related pneumonitis, two patients experienced Grade 5 treatment-related pneumonitis and two patients had >= Grade 3 oesophagitis. Conclusion: SIB-IMRT appears to be an effective therapeutic option in patients with LANSCLC and warrants further evaluation with increased number of patients in prospective clinical trials. Advances in knowledge: This study explores the feasibility of delivering tumoricidal doses of radiation to primary lesions in non-small-cell lung cancer.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Intensity-Modulated Radiotherapy in Treatment of Small Cell Lung Cancer
    Singh, Charu
    Gupta, Shivani
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S787 - S787
  • [22] Volumetric Modulated Arc Therapy and Conventional Intensity-Modulated Radiotherapy for Non-Small-Cell Lung Cancer with Simultaneously Integrated Boost Radiation Therapy :A Planning Comparison Study
    Liu, T.
    Chen, J.
    Zhang, G.
    Sun, T.
    MEDICAL PHYSICS, 2015, 42 (06) : 3524 - 3524
  • [23] Investigating the loco-regional control of simultaneous integrated boost intensity-modulated radiotherapy with different radiation fraction sizes for locally advanced non-small-cell lung cancer: clinical outcomes and the application of an extended LQ/TCP model
    Bo Qiu
    Qi Wen Li
    Xin Lei Ai
    Bin Wang
    Jian Huan
    Zheng Fei Zhu
    Gen Hua Yu
    Ming Ji
    Hai Hang Jiang
    Cheng Li
    Jun Zhang
    Li Chen
    Jin Yu Guo
    Yin Zhou
    Hui Liu
    Radiation Oncology, 15
  • [24] Investigating the loco-regional control of simultaneous integrated boost intensity-modulated radiotherapy with different radiation fraction sizes for locally advanced non-small-cell lung cancer: clinical outcomes and the application of an extended LQ/TCP model
    Qiu, Bo
    Li, Qi Wen
    Ai, Xin Lei
    Wang, Bin
    Huan, Jian
    Zhu, Zheng Fei
    Yu, Gen Hua
    Ji, Ming
    Jiang, Hai Hang
    Li, Cheng
    Zhang, Jun
    Chen, Li
    Guo, Jin Yu
    Zhou, Yin
    Liu, Hui
    RADIATION ONCOLOGY, 2020, 15 (01)
  • [25] Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II - Clinical results
    Lauve, A
    Morris, M
    Schmidt-Ullrich, R
    Wu, QW
    Mohan, R
    Abayomi, O
    Buck, D
    Holdford, D
    Dawson, K
    Dinardo, L
    Reiter, E
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (02): : 374 - 387
  • [26] An esophagus-sparing technique to limit radiation esophagitis in locally advanced non-small cell lung cancer treated by simultaneous integrated boost intensity-modulated radiotherapy and concurrent chemotherapy
    Ma, Li
    Qiu, Bo
    Li, Qiwen
    Chen, Li
    Wang, Bin
    Hu, YongHong
    Liu, MengZhong
    Zhang, Li
    Huang, Yan
    Deng, XiaoWu
    Xia, YunFei
    Lin, MaoSheng
    Liu, Hui
    RADIATION ONCOLOGY, 2018, 13
  • [27] An esophagus-sparing technique to limit radiation esophagitis in locally advanced non-small cell lung cancer treated by simultaneous integrated boost intensity-modulated radiotherapy and concurrent chemotherapy
    Li Ma
    Bo Qiu
    QiWen Li
    Li Chen
    Bin Wang
    YongHong Hu
    MengZhong Liu
    Li Zhang
    Yan Huang
    XiaoWu Deng
    YunFei Xia
    MaoSheng Lin
    Hui Liu
    Radiation Oncology, 13
  • [28] A Comparison of Intensity-Modulated Radiotherapy With Simultaneous Integrated Boost With Three-Dimensional Conformal Radiotherapy With Sequential Boost for Locally Advanced Cervical Cancer: A Dosimetric Study
    Figueredo Negron, Carlos Ivan
    Gamboa Garay, Oscar
    Pabon Giron, Alexandra
    Esguerra Cantillo, Jose Alejandro
    Guerrero Lizcano, Eduardo
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (12)
  • [29] A Dosimetric Comparison of Dose Escalation with Simultaneous Integrated Boost for Locally Advanced Non-Small-Cell Lung Cancer
    Yang, Wenjuan
    Zeng, Biao
    Qiu, Yanfang
    Tan, Jianfeng
    Xu, Shilei
    Cai, Yilong
    Zhou, Yujuan
    Liu, Zhigang
    Luo, Junming
    Wang, Hui
    BIOMED RESEARCH INTERNATIONAL, 2017, 2017
  • [30] Adaptive intensity-modulated radiotherapy with simultaneous integrated boost for stage III non-small cell lung cancer: Is a routine adaptation beneficial?
    Meng, Yinnan
    Luo, Wei
    Xu, Hailing
    Wang, Wei
    Zhou, Suna
    Tang, Xingni
    Li, Zihong
    Zhou, Chao
    Yang, Haihua
    RADIOTHERAPY AND ONCOLOGY, 2021, 158 : 118 - 124